CARM

Insider Trades

Name	Value	Action	Price	Current Price
Klichinsky MichaelChief Scientific Officer $14k57k shares SellOct 7, 2025 $0.2542 --
Klichinsky MichaelChief Scientific Officer $31k119.3k shares SellOct 3, 2025 $0.2604 --
Klichinsky MichaelChief Scientific Officer $51k200k shares SellOct 2, 2025 $0.2543 --
Klichinsky MichaelChief Scientific Officer $42k165k shares SellOct 1, 2025 $0.257 --

News

defenseworld.netCritical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX)defenseworld.netApr 14

Trade CARM

About Carisma Therapeutics, Inc.

Carisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths. Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system. The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.

CEO: Saar Gill
IPO Date: Feb 6, 2014

Market Data

Open: $0.015
High: $0.0324
Low: $0.015
Volume: 10.3K
Avg Volume: 56.1K
52W High: $0.56
52W Low: $0.0001

Valuation

Market Cap: $795k
Enterprise Value: $-1.2M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-60M
Revenue: $20M
Net Income: $-60M
Cash: $18M
Debt: $2.5M

Events

EarningsMay 29

EPS est. -0.1474